Dalcetrapib treatment increased HDL-C and apolipoprotein A1 by 33.7 and 11.8 % , respectively ( both P < 0.001 ) and total cholesterol efflux by 9.5 % ( P = 0.003 ) after 4 weeks , principally via an increase in non-ATP-binding cassette transporter ( ABC ) A1-mediated efflux , without statistically significant changes in pre-1-HDL levels .